CHEC GLP1 RAs: The Good, The Bad and Why We Should Care C-113803

This session explores the ocular implications of GLP-1 receptor agonists, a rapidly growing class of medications used in the treatment of type 2 diabetes and obesity. With increasing patient uptake, it’s essential for optometrists and dispensing opticians to understand potential visual complications such as worsening diabetic retinopathy, vitreous haemorrhage, and NAION. This session will provide practical guidance on clinical monitoring, communication strategies, and referral considerations to support safe, patient-centred care.

“As a valued member of the esteemed CHEC team in the Lancashire area, Dr. Moemen brings over two decades of experience as an accomplished ophthalmic surgeon, having worked across three continents. Providing the highest level of care is his top priority, and he treats each patient with the same dedication and compassion as a cherished family member.

Dr. Moemen places a strong emphasis on continuous growth and professional development. By actively participating in medical conferences and meetings, he shares insights and knowledge with fellow professionals, enhancing expertise that ultimately benefits patient care.

In addition to his clinical work, Dr. Moemen has been actively involved for more than a decade in providing quality eye care through notable charity organisations in Egypt. This impactful work has included treating and performing surgeries for various eye conditions, such as cataract and glaucoma surgeries, further contributing to the well-being of patients both locally and abroad.

At CHEC, Dr. Moemen’s commitment to exceptional patient care and continuous improvement drives the mission to deliver outstanding ophthalmic services in the Lancashire community.”